Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-03-08
2011-03-08
Ha, Julie (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S001100, C514S013500
Reexamination Certificate
active
07902154
ABSTRACT:
The present invention relates to pharmaceutical compositions for treating diseases and conditions caused by ischemia. The pharmaceutical compositions contain a conjugate of a phospholipase (PL) polypeptide and a protein transduction domain (PTD). PLC-δ plays a major role in the regulation of cytosolic calcium levels. During myocardial ischemia, cytosolic calcium accumulation mediates pathogenic changes. According to the present invention, ischemic diseases or conditions leading to hypoxia in tissues, such as the heart and the brain, can be prevented or alleviated by administration of a PTD-PL conjugate.
REFERENCES:
patent: 6166191 (2000-12-01), Randazzo
patent: 2003/0104622 (2003-06-01), Robbins et al.
patent: 2003/0229202 (2003-12-01), Guo et al.
patent: 2005/0090646 (2005-04-01), Sullivan
patent: 2005/0158373 (2005-07-01), Szeto et al.
patent: 2006/0148060 (2006-07-01), Lee et al.
patent: 2007/0105775 (2007-05-01), Lee et al.
patent: 2008/0132450 (2008-06-01), Lee et al.
patent: WO 98/07858 (1998-02-01), None
patent: WO 98/07860 (1998-02-01), None
patent: WO 03/059940 (2003-07-01), None
patent: WO 03/059941 (2003-07-01), None
patent: WO 2004/044008 (2004-05-01), None
patent: WO 2004/078933 (2004-09-01), None
Definition of hypoxia from http://dictionary.reference.com/browse/hypoxia, pp. 1-2, Accessed Aug. 13, 2009.
Alzheimer's disease from http://www.alz.org/alzheimers—disease—what—is—alzheimers.asp, pp. 1-4. Accessed Aug. 13, 2009.
Rudinger J, “Characteristics of the amino acids as components of a peptide hormone sequence,” Peptide Hormones, JA Parsons Edition, University Park Press, Jun. 1976, pp. 1-7.
“Designing Custom Peptides,” from SIGMA Genosys, pp. 1-2. Accessed Dec. 16, 2004.
Schinzel R, Drueckes P, “The phosphate recognition site ofEscherichia colimaltodextrin phosphorylase,” FEBS, Jul. 1991, 286(1,2): 125-128.
Berendesen HJC, “A Glimpse of the Holy Grail?” Science, 1998, 282: 642-643.
Voet D, Voet JG, Biochemistry, Second Edition, John Wiley & Sons, Inc., 1995, pp. 235-241.
Ngo JT, Marks J, Karplus M, “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox,” The Protein Folding Problem and Tertiary Structure Prediction, K. Merc Jr. and S. Le Grand Edition, 1994, pp. 491-495.
Bradley CM, Barrick D, “Limits of Cooperativity in a Structurally Modular Protein: Response of the Notch Ankyrin Domain to Analogous Alanine Substitutions in Each Repeat,” J. Mol. Biol., 2002, 324: 373-386.
Frostbite from Merk manual, pp. 1-3. Accessed Feb. 18, 2010.
Hypothermia from Merck manual, pp. 1-4. Accessed Feb. 16, 2010.
Shock from Merck manual, pp. 1-7. Accessed Feb. 18, 2010.
Alkema, M.J., et al., “Identification of Bmi1-interacting proteins as constituents of a multimeric mammalian Polycomb complex,”Genes&Dev.11:226-240, Cold Spring Harbor Laboratory Press (1997).
Asemu, G., et al., “Identification of the changes in phospholipase C isozymes in ischemic-reperfused rat heart,”Arch. Biochem. Biophys.411:174-182, Elsevier Science (Mar. 2003).
Choi, H.S., et al., “Transduced Tat-α-Synuclein Protects against Oxidative Stress In vitro and In vivo,”J. Biochem. Mol. Biol. 39:253-262, Korean Society for Biochemistry and Molecular Biology (May 2006).
Dent, M.R., et al., “Phospholipase C gene expression, protein content, and activities in cardiac hyperthrophy and heart failure due to volume overload,”Am. J. Physiol. Heart Circ. Physiol. 287:H719-H727, The American Physiological Society (Apr. 2004).
Dietz, G.P.H., et al., “Inhibition of Neuronal Apoptosis in Vitro and in Vivo Using TAT-Mediated Protein Transduction,”Mol. Cell. Neurosci. 21:29-37, Elsevier Science (Sep. 2002).
Gunster, M.J., et al., “Identification and Characterization of Interactions between the Vertebrate Polycomb-Group Protein BMI1 and Human Homologs of Polyhomeotic,”Mol. Cell. Biol17:2326-2335, American Society for Microbiology (1997).
Krief, S., et al., “Identification and Characterization of cvHSP,”J. Biol. Chem.274:36592-36600, The American Society for Biochemistry and Molecular Biology, Inc. (1999).
Kühnel, F., et al., “Protein Transduction Domains Fused to Virus Receptors Improve Cellular Virus Uptake and Enhance Oncolysis by Tumor-Specific Replicating Vectors,”J. Virol.78:13743-13754, American Society for Microbiology (Dec. 2004).
Lai, Y., et al., “Selectively increasing inducible heat shock protein 70 via TAT-protein transduction protects neurons from nitrosative stress excitotoxicity,”J. Neurochem.94:360-366, International Society for Neurochemistry (Jul. 2005).
Lee, K-M., et al., “Molecular Basis of T Cell Inactivation by CTLA-4,”Science282:2263-2266, American Association for the Advancement of Science (1998).
Mangat, R., et al., “Inhibition of phospholipase C-γ1augments the decrease in cardiomyocyte viability by H2O2,”Am. J. Physiol. Heart Circ. Physiol.291:H854-H860, The American Physiological Society (Feb. 2006).
Noguchi, H., et al., “A new cell-permeable peptide allows successful allogenic islet transplantation in mice,”Nat. Med.10:305-309, Nature Publishing Company (Feb. 2004).
Ohta, H., et al., “Structure and Chromosomal Localization of theRAE28/HPH1Gene, A Human Homologue of thePolyhomeoticGene,”DNA Seq.11:61-73, (OPA) Overseas Publishers Association N.V. (2000).
Wheeler, D.S., et al., “Intracellular delivery of HSP70 using HIV-1 Tat protein transduction domain,”Biochem. Biophys. Res. Commun. 301:54-59, Elsevier Science (Jan. 2003).
Yagisawa, H., “Nucleocytoplasmic Shuttling of Phospholipase C-δ1: A Link to Ca2+,”J. Cell. Biochem.97:233-243, Wiley-Liss, Inc. (Oct. 2005).
International Search Report for International Application No. PCT/IB2006/003971, Korean Intellectual Property Office, Republic of Korea, mailed on Sep. 19, 2007.
International Search Report for International Application No. PCT/IB2007/003404, Korean Patent Office, Republic of Korea, mailed on May 2, 2008.
International Search Report for International Application No. PCT/IB2007/004189, Korean Patent Office, Republic of Korea, mailed on Jun. 9, 2008.
Hwang, K.-C., et al., “Phospholipase C-δ1 rescues intracellular Ca2+overload in ischemic heart and hypoxic neonatal cardiomyocotes,”Journal of Steroid Biochemistry and Molecular Biology, 91:131-138, Elsevier Ltd., Holland (2004).
Nalefski, E.A. & Falke, J.J., “The C2 domain calcium-binding motif: Structural and functional diversity,”Protein Science, 5:2375-2390, Cambridge University Press, United Kingdom (1996).
Rebecchi, M.J. & Pentyala, S.N., “Structure, Function, and Control of Phosphoinositide-Specific Phospholipase C,”Physiological Reviews, 80:1291-1335, American Physiological Society, United States (2000).
Written Opinion of the International Searching Authority for International Application No. PCT/IB2007/003404, United States Patent and Trademark Office, Alexandria, Virginia, mailed on May 2, 2008.
Hwang Ki-Chul
Jang Yang-Soo
Lee Sang-Kyou
Lee Seung-Kyou
ForHumanTech. Co., Ltd.
Ha Julie
Sterne Kessler Goldstetin & Fox, P.L.L.C.
LandOfFree
Pharmaceutical composition for alleviation and treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical composition for alleviation and treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition for alleviation and treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2629285